Elizabeth Burke, MD
Dermatology · Salisbury, MDNPI 1740248236
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 882 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations.
Across 882 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Lilly USA, LLC$2K
- Johnson & Johnson$1K
- LEO Pharma Inc.$1K
- Amgen$1K
- Sun Pharmaceutical Industries Inc.$1K
- plus $7K from 28 others
What the payments were for
- Food & beverage$17,12099%
- Education$1441%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 176 | $3,425 |
| Lilly USA, LLC | 66 | $1,664 |
| Johnson & Johnson | 72 | $1,454 |
| LEO Pharma Inc. | 94 | $1,322 |
| Amgen | 56 | $1,277 |
| Sun Pharmaceutical Industries Inc. | 62 | $1,113 |
| Novartis | 58 | $1,049 |
| Pfizer | 68 | $988 |
| Sanofi | 37 | $977 |
| Dermavant Sciences, Inc. | 49 | $960 |
| Regeneron Healthcare Solutions, Inc. | 24 | $472 |
| E.r. Squibb & Sons, L.L.C. | 22 | $428 |
| Incyte Corporation | 13 | $294 |
| UCB, Inc. | 14 | $278 |
| Boehringer Ingelheim | 9 | $223 |
| Mallinckrodt Hospital Products Inc. | 3 | $184 |
| VYNE Pharmaceuticals Inc. | 7 | $179 |
| Genentech USA, Inc. | 9 | $170 |
| Galderma Laboratories, L.p. | 10 | $170 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 8 | $122 |
| Organon | 5 | $102 |
| Prugen, Inc. Pharmaceuticals | 2 | $95 |
| Arcutis Biotherapeutics, Inc. | 5 | $75 |
| Kyowa Kirin, Inc. | 2 | $39 |
| Verrica Pharmaceuticals Inc. | 2 | $36 |
| Hill Dermaceuticals, Inc. | 1 | $28 |
| Almirall LLC | 1 | $23 |
| Revance Therapeutics, Inc. | 1 | $22 |
| Biofrontera Inc. | 1 | $19 |
| Bristol Myers Squibb | 1 | $18 |
| Springworks Therapeutics, Inc. | 1 | $18 |
| Janssen Scientific Affairs, LLC | 1 | $16 |
| Medtronic | 1 | $14 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,264 in reported general payments places this provider in the 85th percentile of 306 dermatology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 16 | $327,966 |
| Taltz AutoinjectorIxekizumab | 25 | $169,537 |
| Humira(Cf)Adalimumab | 14 | $95,071 |
| Tacrolimus | 291 | $61,271 |
| Dupixent SyringeDupilumab | 13 | $48,356 |
| VtamaTapinarof | 27 | $37,079 |
| OpzeluraRuxolitinib Phosphate | 15 | $29,007 |
| Doxycycline Hyclate | 239 | $16,679 |
| Azelaic Acid | 183 | $16,553 |
| Fluorouracil | 161 | $10,711 |
| Tretinoin | 100 | $10,414 |
| Metronidazole | 80 | $7,045 |
| Pimecrolimus | 20 | $6,066 |
| Acitretin | 30 | $5,940 |
| Fluocinolone AcetonideFluocinolone/Shower Cap | 104 | $5,042 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf) | $3,425 | $95,07114 claims |
| Dermavant Sciences, Inc.Vtama | $960 | $37,07927 claims |
| Incyte CorporationOpzelura | $294 | $29,00715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 306 dermatology providers in Maryland.
Other dermatology in Salisbury
- Luette SemmesSalisbury$19K
- Benjamin LockshinSilver Spring$4M
- Shawn KwatraBaltimore$1.1M
- Chesahna Kindred WeaverMarriottsville$837K
- Oanh LauringNottingham$763K
- Ronald PrussickN Bethesda$620K
- Rebecca KazinChevy Chase$342K
- Susan WalkerBethesda$221K
- Monte MeltzerBerlin$220K
- Valerie CallenderGlenn Dale$183K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.